Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NovoCure Limited - Ordinary Shares (NQ:NVCR)

12.07 -0.02 (-0.17%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NovoCure Limited - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
7 Nasdaq Stocks Down 59% Set to Soar at Least 141%
Wall Street always think companies are high-growth potential stocks but a little circumspection is required before buying 
Via InvestorPlace
FCEL Stock Alert: FuelCell Energy Announces AI Deal With IBM
FuelCell Energy stock is climbing higher on Tuesday as investors in FCEL celebrate the company signing a deal with IBM! 
Via InvestorPlace
Topics Artificial Intelligence
Novocure Layoffs 2023: What to Know About the Latest NVCR Job Cuts
Novocure layoffs are coming for 13% of the company's workers as it seeks to reduce its headcount by 200 people to reduce costs. 
Via InvestorPlace
Topics Workforce
Novocure Announces Portfolio Prioritization and Strategic Restructuring Plan Focused on Near-term Growth Drivers and an Accelerated Path to Profitability
From Novocure
Via Business Wire
Is Novocure Stock a Buy?
The stock isn't far from its 52-week low. 
Via The Motley Fool
Why Novocure Stock Fell 24.4% This Week
Novocure announced a disappointing outcome from a phase 3 clinical trial for a key cancer treatment. 
Via The Motley Fool
What 11 Analyst Ratings Have To Say About NovoCure
 
Via Benzinga
Novocure to Participate in 35th Annual Piper Sandler Healthcare Conference
From Novocure
Via Business Wire
Novocure Announces Presentations on Tumor Treating Fields Therapy, Including New Clinical Data and Real-World Evidence, at 2023 Society for Neuro-Oncology Annual Meeting
From Novocure
Via Business Wire
Why Novocure Stock Was Sick Today
Investors weren't particularly pleased with the company's third-quarter performance. 
Via The Motley Fool
NovoCure (NVCR) Q3 2023 Earnings Call Transcript
NVCR earnings call for the period ending September 30, 2023. 
Via The Motley Fool
Topics Earnings
Novocure Reports Third Quarter 2023 Financial Results
From Novocure
Via Business Wire
Novocure Announces Presence at European Society for Medical Oncology (ESMO) Congress 2023
From Novocure
Via Business Wire
Novocure and Stanford School of Medicine to Establish Tumor Treating Fields Research Program
From Novocure
Via Business Wire
NovoCure Limited (NASDAQ:NVCR) Long Term Shareholder Notice: Investigation of Potential Wrongdoing
San Diego, CA -- (SBWIRE) -- 10/10/2023 -- An investigation was announced for investors in shares of NovoCure Limited (NASDAQ:NVCR) concerning potential breaches of fiduciary duties by certain... 
Via SBWire
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Novocure to Report Third Quarter 2023 Financial Results
From Novocure
Via Business Wire
Novocure Announces Presence at American Society for Radiation Oncology (ASTRO) 2023 Annual Meeting
From Novocure
Via Business Wire
Stocks That Hit 52-Week Lows On Friday
  Friday's session saw 112 companies set new 52-week lows. 
Via Benzinga
3 Things About NovoCure That Smart Investors Know
Its cancer-treating device is struggling to find its market. 
Via The Motley Fool
Novocure Highlights Use of Tumor Treating Fields Therapy in Treatment of Non-Small Cell Lung Cancer at 2023 World Conference on Lung Cancer
From Novocure
Via Business Wire
3 Healthcare Stocks to Sell in September Before They Crash & Burn
The prognosis for these healthcare stocks isn't optimistic so plan to sell them this month before they get worse. 
Via InvestorPlace
Down 31% in 1 Day, What's Next for NovoCure Stock?
It's entering a risky period, but it could persevere. 
Via The Motley Fool
Is NovoCure's Stock Headed for a Free Fall?
It can be hard to find a reason to remain bullish on NovoCure. 
Via The Motley Fool
Novocure Announces The Lancet Oncology Publishes Primary Data from Phase 3 LUNAR Clinical Trial in Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
From Novocure
Via Business Wire
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 99 stocks hit new 52-week lows. 
Via Benzinga
What's Going On With NovoCure Stock Today?
NovoCure Limited (NASDAQ: NVCR) shares are trading higher Tuesday. The stock appears to be recovering from a loss of over 30% on Monday. What To Know: 
Via Benzinga
PDD Holdings, UP Fintech Holding, Big Lots And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded higher, with the Dow Jones gaining around 100 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Dow Gains Over 100 Points; Hawaiian Electric Shares Surge
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining over 100 points on Monday. The Dow traded up 0.42% to 34,490.80 while the NASDAQ rose 0.62% to 13,674.49. The S&P 500,... 
Via Benzinga
Topics Stocks
Why Is Novocure (NVCR) Stock Down 30% Today?
Following Novocure’s disappointing late-stage clinical trial for its cancer-treating platform, NVCR stock stumbled on relevancy concerns. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.